Efeitos do uso de agomelatina, vortioxetina e cetamina durante a gravidez e período de lactação no desenvolvimento infantil

Abstract

Due to its high prevalence and the different consequences for women, their families, and society, this study aims to collect information about exposure to vortioxetine, agomelatine, and ketamine throughout pregnancy and lactation, in addition to comparing with the drug most used in the clinic, sertraline, for the treatment of pre and postpartum depression. PubMed searches were performed from June 2021 to December 2021 with keywords “vortioxetine” and “agomelatine” associated with “breast milk”, “breastfeeding” and “pregnancy”, in addition to “ketamine” associated with "breast milk", "breastfeeding", "depression in pregnancy", the last one being filtered by "clinical trial" in the last ten years. Data regarding the use of agomelatine, vortioxetine and ketamine are still very scarce, but they seem promising as no side effects have been reported in infants. Depending on the severity and degree of recurrence of the underlying disease, when the patient is already stabilized on a specific antidepressant, a recent expert panel advises that the same drug should be continued, except for paroxetine. More clinically relevant studies and more robust data on the use of agomelatine, vortioxetine and ketamine are needed before conclusions can be drawn regarding their safety profiles for pregnant and lactating women.